Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MDMA-assisted Therapy for PTSD (NUMCAP1)
NCT04968938Phase 2Withdrawn
- Sponsor
- Lykos Therapeutics
- Start
- Aug 2022
- Primary completion
- Aug 2023
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of midomafetamine in post-traumatic stress disorder (PTSD), sponsored by Lykos Therapeutics. Planned start Aug 2022; status: withdrawn.
02
Drugs
midomafetamine
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NCT04968938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04968938.